Mitochon Pharmaceuticals » Logo

Emily's Entourage Announces $178,882 in Funding for Cystic Fibrosis Research

In February 2022, we announced that Emily’s Entourage (EE) awarded $440,000 in funding for two new grants to advance cystic fibrosis (CF) research and drug development. Today, we are thrilled to share that EE has awarded an additional $178,882 to a third grant recipient, Mitochon Pharmaceuticals, Inc., to advance research into mitochondrial dysfunction in those with CF.

Additional information on this grant is available below.

GRANT RECIPIENT: Therapeutic utility of MP-101 for cystic fibrosis

Robert Alonso, MBA, CEO and co-founder
John G. Geisler, PhD, CSO and co-founder

Mitochon Pharmaceuticals, Inc.

Mitochondrial dysfunction is an often overlooked issue in people with CF. It is marked by impaired energy production and the generation of huge levels of free radicals that are toxic to all cells in the body. Mitochon’s work ​​represents a novel approach for CF in its use of a mitochondrial modulator, MP-101, to reduce free radical production and mitochondrial calcium overload, thereby reducing inflammatory responses and consequent tissue damage. MP-101 will be tested in a ferret model of CF and, if successful, could be tested in patients with CF.

About Mitochon Pharmaceuticals
Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival—similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Mitochon is supported by Ben Franklin Technology Partners Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.
crosschevron-upchevron-down